Related Experiment Video
Updated: May 12, 2026

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating
Published on: June 23, 2018
Heparanase patents: dim past and bright future
Nicola J Nasser1, Eviatar Nevo
1Institute of Oncology, Davidoff Center, Rabin Medical Center Beilinson Campus, Petah Tikva 49100, Israel. nicola.nasser@gmail.com
Abstract:
Heparanase is an enzyme expressed normally in platelets and in placenta at high levels, and is undetectable in other normal human tissues. Heparanase degrades the heparan sulfate saccharides of the extracellular matrix. The real problem starts when tumor cells express heparanase; this results in increased tumor angiogenesis, aggressiveness, and metastasis. Patents filed on heparanase detection, suppression, and function modulation were not translated yet into products (tested in Phase III trials). The mismatch between researchers, clinicians, and pharmaceutical companies, which identified the first 20 years of heparanase research, is changing and will hopefully foster the arrival of some of these patent inventions for clinical applicability.
Related Concept Videos
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Sanger Sequencing
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Maxam-Gilbert Sequencing
Challenges of the Maxam-Gilbert Method
The...

